| One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial H Joensuu, M Eriksson, KS Hall, JT Hartmann, D Pink, J Schütte, ... Jama 307 (12), 1265-1272, 2012 | 1157 | 2012 |
| Soft tissue and visceral sarcomas: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ... Annals of Oncology 29, iv51-iv67, 2018 | 864 | 2018 |
| Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo–purged stem cell rescue: a nonrandomized phase 2 … CH Geisler, A Kolstad, A Laurell, NS Andersen, LB Pedersen, ... Blood, The Journal of the American Society of Hematology 112 (7), 2687-2693, 2008 | 757 | 2008 |
| Gastrointestinal stromal tumours: ESMO–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, N Abecassis, S Bauer, R Biagini, S Bielack, S Bonvalot, ... Annals of Oncology 29, iv68-iv78, 2018 | 575 | 2018 |
| Malignant lymphoma and exposure to chemicals, especially organic solvents, chlorophenols and phenoxy acids: a case-control study L Hardell, M Eriksson, P Lenner, E Lundgren British journal of cancer 43 (2), 169-176, 1981 | 571 | 1981 |
| Bone sarcomas: ESMO–PaedCan–EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, S Bielack, N Abecassis, HT Aro, S Bauer, R Biagini, ... Annals of Oncology 29, iv79-iv95, 2018 | 523 | 2018 |
| Comparison of MAPIE versus MAP in patients with a poor response to preoperative chemotherapy for newly diagnosed high-grade osteosarcoma (EURAMOS-1): an open-label … NM Marina, S Smeland, SS Bielack, M Bernstein, G Jovic, MD Krailo, ... The Lancet Oncology 17 (10), 1396-1408, 2016 | 475 | 2016 |
| Soft-tissue sarcomas and exposure to chemical substances: a case-referent study. M Eriksson, L Hardell, NO Berg, T Möller, O Axelson Occupational and Environmental Medicine 38 (1), 27-33, 1981 | 426 | 1981 |
| A case–control study of non‐Hodgkin lymphoma and exposure to pesticides L Hardell, M Eriksson Cancer 85 (6), 1353-1360, 1999 | 421 | 1999 |
| Methotrexate, doxorubicin, and cisplatin (MAP) plus maintenance pegylated interferon alfa-2b versus MAP alone in patients with resectable high-grade osteosarcoma and good … SS Bielack, S Smeland, JS Whelan, N Marina, G Jovic, JM Hook, ... Journal of Clinical Oncology 33 (20), 2279, 2015 | 390 | 2015 |
| EURAMOS-1, an international randomised study for osteosarcoma: results from pre-randomisation treatment JS Whelan, SS Bielack, N Marina, S Smeland, G Jovic, JM Hook, M Krailo, ... Annals of oncology 26 (2), 407-414, 2015 | 332 | 2015 |
| Nordic MCL 2 trial update: six‐year follow‐up after intensive immunochemotherapy for untreated mantle cell lymphoma followed by BEAM or BEAC+ autologous stem‐cell support … CH Geisler, A Kolstad, A Laurell, M Jerkeman, R Räty, NS Andersen, ... British journal of haematology 158 (3), 355-362, 2012 | 326 | 2012 |
| Oral snuff, smoking habits and alcohol consumption in relation to oral cancer in a Swedish case‐control study EB Schildt, M Eriksson, L Hardell, A Magnuson International Journal of Cancer 77 (3), 341-346, 1998 | 289 | 1998 |
| Gastrointestinal stromal tumours: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up PG Casali, JY Blay Annals of Oncology 21, v98-v102, 2010 | 286 | 2010 |
| Increased concentrations of polychlorinated biphenyls, hexachlorobenzene, and chlordanes in mothers of men with testicular cancer. L Hardell, B van Bavel, G Lindström, M Carlberg, AC Dreifaldt, ... Environmental Health Perspectives 111 (7), 930-934, 2003 | 280 | 2003 |
| Pesticide exposure as risk factor for non‐Hodgkin lymphoma including histopathological subgroup analysis M Eriksson, L Hardell, M Carlberg, M Åkerman International journal of cancer 123 (7), 1657-1663, 2008 | 248 | 2008 |
| Exposure to pesticides as risk factor for non-Hodgkin's lymphoma and hairy cell leukemia: pooled analysis of two Swedish case-control studies L Hardell, M Eriksson, M Nordström Leukemia & lymphoma 43 (5), 1043-1049, 2002 | 239 | 2002 |
| Adjuvant imatinib for high-risk GI stromal tumor: analysis of a randomized trial H Joensuu, M Eriksson, K Sundby Hall, A Reichardt, JT Hartmann, D Pink, ... Journal of Clinical Oncology 34 (3), 244-250, 2016 | 234 | 2016 |
| Exposure to dioxins as a risk factor for soft tissue sarcoma: a population-based case-control study M Eriksson, L Hardell, HO Adami JNCI: Journal of the National Cancer Institute 82 (6), 486-490, 1990 | 223 | 1990 |
| 15‐year follow‐up of the Second Nordic Mantle Cell Lymphoma trial (MCL 2): prolonged remissions without survival plateau CW Eskelund, A Kolstad, M Jerkeman, R Räty, A Laurell, S Eloranta, ... British journal of haematology 175 (3), 410-418, 2016 | 220 | 2016 |
